Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > News Brief: $AGN CEO Chris Moreau Begins TBI Research AP-188
View:
Post by bmreed on Feb 23, 2023 3:18pm

News Brief: $AGN CEO Chris Moreau Begins TBI Research AP-188

News Brief: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Initiates Traumatic Brain Injury (TBI) Research Program with AP-188 - https://youtu.be/sN5fFFvCPHc

 

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With AP-188; Appoints Global TBI Expert as Advisor

Comment by waves1 on Feb 27, 2023 5:24pm
It's great to see AGN expanding its portfolio, especially given this program can be accelerated directly to Phase 2 in Q4 2023 with the data from its Phase 1 DMT study for stroke
Algernon Pharmaceuticals Inc